quick facts about schedule II drugs (C-II drugs)

Source: U.S. Drug Enforcement Administration (DEA)

examples of schedule II drugs (C-II drugs)
generic namebrand namedrug class or drug categorygeneral use
amphetamine/dextroamphetamineAdderallcentral nervous system stimulantADHD
dextroamphetamineDexedrinecentral nervous system stimulantattention-deficit hyperactivity disorder (ADHD)
fentanylDuragesicnarcotic analgesicchronic pain
fentanyl citrateActiq; Fentora; Onsolisnarcotic (opioid) analgesicto manage breakthrough pain in cancer patients
hydrocodone/acetaminophenLortab; Norco; Vicodin; Hycetnarcotic analgesicto relieve moderate to severe pain
hydrocodone/chlorpheniramineTussicapsnarcotic cough suppressant and antihistamineto treat symptoms due to cough, colds, allergies, or flu
hydrocodone/chlorpheniramineTussionexnarcotic antitussive and antihistamineto treat symptoms due to cough, colds, allergies, or flu
hydrocodone, chlorpheniramine, pseudoephedrineZutriproantitussive, antihistamine and nasal decongestantfor the relief of cough, nasal congestion, and upper respiratory allergies
hydrocodone/ibuprofenVicoprofennarcotic (opioid) analgesicshort-term pain relief
hydrocodone/homatropineHycodan; Hydrometanticholinergic and narcotic cough suppressantindicated for the symptomatic relief of cough
hydromorphoneDilaudid; Exalgonarcotic analgesic; opioid agonistto treat moderate to severe pain
lisdexamfetamineVyvansecentral nervous system stimulantattention deficit hyperactivity disorder (ADHD)
meperidineDemerolnarcotic analgesicto treat moderate to severe pain
methadoneDolophine; Methadosenarcotic analgesic; narcotic suppressantto treat severe pain; to treat narcotic addiction
methylphenidate (oral)Concerta; Ritalin; Methylincentral nervous system stimulantADHD
methylphenidate (patch)Daytranacentral nervous system stimulantADHD
morphine sulfateMS Contin; Kadian; Avinza; Oramorphnarcotic analgesicmoderate to severe pain
oxycodoneOxyContin; Roxicodonenarcotic analgesicmoderate to severe pain
oxycodone/acetaminophenPercocetnarcotic analgesicmoderate to severe pain
oxymorphoneOpananarcotic pain relieverto treat moderate-to-severe pain
tapentadolNucyntaopioid analgesicmoderate to severe acute pain
Schedule II same as C-II
--- substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence.

--- there are no refills for a C-II prescription.

--- federal law requires the patient's street address on Rx's for controlled substances.

--- prescriptions for Schedule II controlled substances must be written and be signed by the practitioner.

--- a C-II prescription must have the control number, physician's DEA number, and physician's DPS number.

--- in some states, a C-II prescription must be filled within 7 days of issue and in other states it must be filled within 72 hours. In Texas, a C-II prescription must be filled within 21 days of issue.

--- labels for C-II controlled substances must contain the fill date.

--- for C-II drugs, the auxiliary label "Transfer Warning" is required.

--- labels for C-II drugs should contain the statement, "Caution: Federal law prohibits the transfer of this drug to any person other than the person for whom it was prescribed."

--- after a pharmacist fills a C-II prescription, the pharmacist must sign and date the original prescription and this prescription must be filed separately from other prescriptions.

--- schedule II controlled substance prescriptions, written for a patient enrolled in hospice, may be faxed to a pharmacy for dispensing.

--- physician assistants (PA) and advanced practice nurses (APN) are not allowed to issue prescriptions for C-II drugs.

--- in emergency situations, a prescription for a Schedule II controlled substance may be telephoned to the pharmacy and the prescriber must follow up with a written prescription being sent to the pharmacy within 72 hours.

--- a DEA triplicate form 222 must be used when ordering C-II drugs. Purchase of C-II drugs must be authorized by a pharmacist on the DEA form.

--- a physical inventory of C-II drugs is required every two years.

© 2006